PHG Foundation examines health-policy implications of updated BOADICEA breast-cancer risk model
A new policy analysis from the PHG Foundation considers what an updated, polygenic-score-integrated BOADICEA model means for how familial breast-cancer risk should be assessed at a population level.
The PHG Foundation (University of Cambridge) has published a policy-focused commentary examining the implications of recent developments in the BOADICEA (Breast and Ovarian Analysis of Disease Incidence and Carrier Estimation Algorithm) model, which underpins CanRisk — the web-based tool used in UK clinical genetics services to estimate an individual woman's risk of hereditary breast and ovarian cancer syndromes.
The commentary focuses on BOADICEA's integration of polygenic risk scores alongside established high-penetrance gene variants such as BRCA1 and BRCA2, which allows the model to produce more granular risk stratification than was possible using monogenic information alone. PHG Foundation considers what this means for health-system design: whether population-level risk assessment should be offered more broadly, how models like CanRisk interact with existing NICE guidance on familial breast cancer, and what data-governance and equity considerations arise when polygenic scores derived from predominantly European ancestry populations are applied more widely.
The piece is a policy analysis rather than an original empirical study; it does not present new clinical data. PHG Foundation is an independent health-policy research group embedded within the University of Cambridge and has a longstanding focus on the responsible implementation of genomics in public health.
For genetic counsellors, clinical geneticists, and health-policy researchers, the commentary offers a useful synthesis of where BOADICEA and CanRisk currently sit in the policy landscape and what systemic questions remain unresolved as polygenic risk tools mature.
Plain-language version
For patients, families, and general readers. Educational only — not medical advice.
BOADICEA is a computer programme that doctors and genetic counsellors use to estimate how likely someone is to have an inherited form of breast or ovarian cancer based on their family history and genetic information. It powers a tool called CanRisk, used in UK genetics services.
Researchers at the PHG Foundation have published a piece examining what improvements to this programme — including the addition of something called a polygenic risk score, which looks at many small genetic differences together rather than one large gene change — might mean for how healthcare systems offer this kind of risk assessment in future.
The article is about health policy and systems, not about individual results. It raises questions about fairness, data use, and how guidelines might need to change as the science develops.
This is an educational summary, not medical advice. If anything here raises questions for you, please speak with your GP or a clinical professional.
Sources
Read the original reporting — these are the public sources this summary draws from.
-
Primary source PHG Foundation · 2026-08-11What the BOADICEA breakthrough means for health policy